 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Hims & Hers Health, Inc. (HIMS) operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally.
The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care.
In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category.
Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners.
Hims & Hers Health, Inc. is based in San Francisco, California.
Hims & Hers Health, Inc. is expanding its product offerings with the addition of GLP-1 injections to its weight loss treatments, enhancing customer access to affordable and high-quality options amid branded medication shortages. Recent financials show a significant revenue jump to US$278.17 million in Q1 2024 from the previous year, turning a prior net loss into a profit of US$11.13 million. Insider transactions have been positive with more buying than selling in recent months, reflecting confidence from those closest to the company. However, shareholder dilution has occurred over the past year and revenue growth projections are slightly below industry standards at 17.8% annually.
Entry Point: $24.00
Trading Range: $5.65 - $25.50
Stop Loss: $22.80
Target Price: $26.40
